Patent intelligence · US
US 9738721
Oncostatin M receptor antigen binding proteins
Oncostatin M receptor antigen binding proteins
Patent details — US 9738721
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 22, 2017
- Expiration
- Aug 17, 2037
- Applicant
- Kiniksa Pharmaceuticals, GmbH
- Claims
- 16
- CPC classes
- A61K, A61K39/395, A61P, A61P1/16
Quick answer
US 9738721 (Oncostatin M receptor antigen binding proteins) is held by Kiniksa Pharmaceuticals, GmbH. Status: granted. Granted Aug 22, 2017. Expires Aug 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kiniksa Pharmaceuticals, GmbH
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K39/395, A61P, A61P1/16, A61P1/18, A61P11/00
More from Kiniksa Pharmaceuticals, GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12234294
Pharmaceutical composition of a humanized anti-CD40 antibody
granted -
US 12122837
Oncostatin M receptor antigen binding proteins
granted -
US 11141479
Stable anti-OSMR antibody formulation
granted -
US 10493149
Stable anti-OSMR antibody formulation
granted -
US 10421813
Oncostatin M receptor antigen binding proteins
granted -
US 10391170
Stable anti-OSMR antibody formulation
granted -
US 9663571
Oncostatin M receptor antigen binding proteins
granted
Frequently asked questions
What is US patent 9738721?
US 9738721 (Oncostatin M receptor antigen binding proteins) is held by Kiniksa Pharmaceuticals, GmbH. Status: granted. Granted Aug 22, 2017. Expires Aug 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9738721?
Kiniksa Pharmaceuticals, GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 9738721 expire?
Our index shows an expiration date of Aug 17, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.